How diagnosis-related group 559 will change the US medicare cost reimbursement ratio for stroke centers

Bart M Demaerschalk, Donna L. Durocher

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE - Thrombolysis for acute ischemic stroke saves societal costs, but hospitals that practice acute stroke care appear to shoulder the burden of the cost, which exceeds reimbursement. With creation of the diagnosis-related group (DRG) 559, the US Centers for Medicare and Medicaid Services pays hospitals approximately US $6000 more per case when thrombolysis is administered. We sought to determine the total cost of, and reimbursement for, acute stroke treatment with thrombolysis at a single stroke center and the economic impact of DRG 559. METHODS - Between September 2001 and December 2004, we collected data on all patients with acute stroke who received thrombolysis. We identified all hospital costs and reimbursement per patient. Financial results were expressed as a cost-reimbursement ratio: average total cost to average total reimbursement per patient. We then reanalyzed data using the projected Medicare hospital reimbursement with DRG 559. RESULTS - Sixty-seven patients with stroke (mean age, 72 years) were treated (mean length of stay, 4.4 days; mean stroke severity, National Institutes of Health Stroke Scale score of 15; and symptomatic intracranial hemorrhage rate, 7%). The cost-reimbursement ratio was 1.41 (95% CI=0.98 to 2.28) before DRG 559 and estimated to be 0.82 (95% CI=0.66 to 0.97) after DRG 559. CONCLUSIONS - Our hospital costs have traditionally exceeded Medicare reimbursement for the acute care of thrombolyzed patients with ischemic stroke, but with DRG 559, a new economically favorable cost-reimbursement ratio for hospitals will be established.

Original languageEnglish (US)
Pages (from-to)1309-1312
Number of pages4
JournalStroke
Volume38
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Diagnosis-Related Groups
Medicare
Stroke
Costs and Cost Analysis
Hospital Costs
Centers for Medicare and Medicaid Services (U.S.)
Intracranial Hemorrhages
National Institutes of Health (U.S.)
Length of Stay
Patient Care
Economics

Keywords

  • Ischemic
  • Reimbursement
  • Stroke
  • Stroke treatment
  • Thrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)
  • Medicine(all)

Cite this

How diagnosis-related group 559 will change the US medicare cost reimbursement ratio for stroke centers. / Demaerschalk, Bart M; Durocher, Donna L.

In: Stroke, Vol. 38, No. 4, 04.2007, p. 1309-1312.

Research output: Contribution to journalArticle

@article{174fbde161c94b1e95447d78ae2e4218,
title = "How diagnosis-related group 559 will change the US medicare cost reimbursement ratio for stroke centers",
abstract = "BACKGROUND AND PURPOSE - Thrombolysis for acute ischemic stroke saves societal costs, but hospitals that practice acute stroke care appear to shoulder the burden of the cost, which exceeds reimbursement. With creation of the diagnosis-related group (DRG) 559, the US Centers for Medicare and Medicaid Services pays hospitals approximately US $6000 more per case when thrombolysis is administered. We sought to determine the total cost of, and reimbursement for, acute stroke treatment with thrombolysis at a single stroke center and the economic impact of DRG 559. METHODS - Between September 2001 and December 2004, we collected data on all patients with acute stroke who received thrombolysis. We identified all hospital costs and reimbursement per patient. Financial results were expressed as a cost-reimbursement ratio: average total cost to average total reimbursement per patient. We then reanalyzed data using the projected Medicare hospital reimbursement with DRG 559. RESULTS - Sixty-seven patients with stroke (mean age, 72 years) were treated (mean length of stay, 4.4 days; mean stroke severity, National Institutes of Health Stroke Scale score of 15; and symptomatic intracranial hemorrhage rate, 7{\%}). The cost-reimbursement ratio was 1.41 (95{\%} CI=0.98 to 2.28) before DRG 559 and estimated to be 0.82 (95{\%} CI=0.66 to 0.97) after DRG 559. CONCLUSIONS - Our hospital costs have traditionally exceeded Medicare reimbursement for the acute care of thrombolyzed patients with ischemic stroke, but with DRG 559, a new economically favorable cost-reimbursement ratio for hospitals will be established.",
keywords = "Ischemic, Reimbursement, Stroke, Stroke treatment, Thrombolysis",
author = "Demaerschalk, {Bart M} and Durocher, {Donna L.}",
year = "2007",
month = "4",
doi = "10.1161/01.STR.0000260185.74694.a7",
language = "English (US)",
volume = "38",
pages = "1309--1312",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - How diagnosis-related group 559 will change the US medicare cost reimbursement ratio for stroke centers

AU - Demaerschalk, Bart M

AU - Durocher, Donna L.

PY - 2007/4

Y1 - 2007/4

N2 - BACKGROUND AND PURPOSE - Thrombolysis for acute ischemic stroke saves societal costs, but hospitals that practice acute stroke care appear to shoulder the burden of the cost, which exceeds reimbursement. With creation of the diagnosis-related group (DRG) 559, the US Centers for Medicare and Medicaid Services pays hospitals approximately US $6000 more per case when thrombolysis is administered. We sought to determine the total cost of, and reimbursement for, acute stroke treatment with thrombolysis at a single stroke center and the economic impact of DRG 559. METHODS - Between September 2001 and December 2004, we collected data on all patients with acute stroke who received thrombolysis. We identified all hospital costs and reimbursement per patient. Financial results were expressed as a cost-reimbursement ratio: average total cost to average total reimbursement per patient. We then reanalyzed data using the projected Medicare hospital reimbursement with DRG 559. RESULTS - Sixty-seven patients with stroke (mean age, 72 years) were treated (mean length of stay, 4.4 days; mean stroke severity, National Institutes of Health Stroke Scale score of 15; and symptomatic intracranial hemorrhage rate, 7%). The cost-reimbursement ratio was 1.41 (95% CI=0.98 to 2.28) before DRG 559 and estimated to be 0.82 (95% CI=0.66 to 0.97) after DRG 559. CONCLUSIONS - Our hospital costs have traditionally exceeded Medicare reimbursement for the acute care of thrombolyzed patients with ischemic stroke, but with DRG 559, a new economically favorable cost-reimbursement ratio for hospitals will be established.

AB - BACKGROUND AND PURPOSE - Thrombolysis for acute ischemic stroke saves societal costs, but hospitals that practice acute stroke care appear to shoulder the burden of the cost, which exceeds reimbursement. With creation of the diagnosis-related group (DRG) 559, the US Centers for Medicare and Medicaid Services pays hospitals approximately US $6000 more per case when thrombolysis is administered. We sought to determine the total cost of, and reimbursement for, acute stroke treatment with thrombolysis at a single stroke center and the economic impact of DRG 559. METHODS - Between September 2001 and December 2004, we collected data on all patients with acute stroke who received thrombolysis. We identified all hospital costs and reimbursement per patient. Financial results were expressed as a cost-reimbursement ratio: average total cost to average total reimbursement per patient. We then reanalyzed data using the projected Medicare hospital reimbursement with DRG 559. RESULTS - Sixty-seven patients with stroke (mean age, 72 years) were treated (mean length of stay, 4.4 days; mean stroke severity, National Institutes of Health Stroke Scale score of 15; and symptomatic intracranial hemorrhage rate, 7%). The cost-reimbursement ratio was 1.41 (95% CI=0.98 to 2.28) before DRG 559 and estimated to be 0.82 (95% CI=0.66 to 0.97) after DRG 559. CONCLUSIONS - Our hospital costs have traditionally exceeded Medicare reimbursement for the acute care of thrombolyzed patients with ischemic stroke, but with DRG 559, a new economically favorable cost-reimbursement ratio for hospitals will be established.

KW - Ischemic

KW - Reimbursement

KW - Stroke

KW - Stroke treatment

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=34247899150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247899150&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000260185.74694.a7

DO - 10.1161/01.STR.0000260185.74694.a7

M3 - Article

C2 - 17332446

AN - SCOPUS:34247899150

VL - 38

SP - 1309

EP - 1312

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 4

ER -